
About this episode
Keith Levy, Operating Partner at Sonoma Brands
Every company must have a strong capital allocation strategy to maximize its potential. Without it, the company may end up missing opportunities and spending money on things that won't help it grow or become more profitable.
In this episode of the M&A Science Podcast, Keith Levy, Operating Partner at Sonoma Brands, shares his experience on successful and unsuccessful capital allocation strategies.
Things you will learn in this episode:
• Strategy vs IRR
• Venture capital vs recapitalization strategy
• Minority vs majority recapitalization
• Evaluating exit strategy
This episode is sponsored by the DealRoom
Ready to take your M&A to the next level with software made to manage each stage of the deal process? See how DealRoom can facilitate your next deal at https://dealroom.net
******************
Episode Bookmarks
00:00 Intro
11:27 Focusing on organic growth
16:37 Post-merger integration execution
25:01 Strategy vs IRR
26:59 Handling projections
28:07 Integration with Mars
36:20 Role of an operating partner
42:07 Big company vs Small company in M&A
43:39 Venture capital vs recapitalization strategy
48:44 Cashing out from an owner's perspective
50:42 Minority vs majority recapitalization
54:03 Impact of valuations and interest rates on investment decisions
59:07 Timing on investments
1:01:25 Evaluating exit strategy
1:03:46 Advice for practitioners
1:05:41 Craziest thing in M&A
Get every episode summarized
Each time M&A Science publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from M&A Science

Cultural Fit Over EBITDA: How Salas O'Brien Built a 30-Merger Program Without a...
M&A Science

Cross-Border M&A: How to Do Deals in Italy with Mauro Sambati and Donato Romano
M&A Science

Four Questions That Defined a $1 Billion Deal with Robert Lovegrove
M&A Science

Stop Falling in Love with the Deal: Guardrails for High-Volume Acquisitions with...
M&A Science